胃癌治疗原则和化疗方案-医学课件.pptVIP

REAL-2: 疗效（Efficacy） Efficacy ECFN=263 ECXN=250 EOFN=245 EOXN=244 P: ECF vs EOX RR (%) 41 46 42 48 1 year OS (%) 37.7 40.8 40.4 46.8 OS (mo) 9.9 9.9 9.3 11.2 0.025 Cunningham et al. ASCO 2006 LBA 4017 REAL-2: 总生存* 卡培他滨 非劣效于静脉 5-FU 奥沙利铂非劣效于顺铂 Capecitabine (n=480) 5-FU (n=484) 10.9 9.6 12 Estimated probability 24 36 0.8 0.6 0.4 0.2 0.0 1.0 HR=0.86 (95% CI: 0.80–0.99) *Per protocol population Months 24 48 72 12 36 10.4 10.0 HR=0.92 (95% CI: 0.8–1.1) 60 1.0 0.8 0.6 0.4 0.2 0.0 Oxaliplatin (n=474) Cisplatin (n=490) Estimated probability Months 0 0 Cunningham et al. NEJ